GlassScriptPhysician profile
Julie Ladd
NPI 1154980159
$1,127.04
in general payments reported to CMS, 2019-2025
21 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $512 · 2022: $235 · 2024: $188 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.18 | 2021 | |
| Acadia Pharmaceuticals INC | $120.06 | 2021 | |
| Urovant Sciences INC | $112.92 | 2022 | |
| Avanir Pharmaceuticals, INC. | $109.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $102.00 | 2024 | Voquezna |
| Janssen Biotech, INC. | $99.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $92.16 | 2021-2025 | |
| Viatris Specialty LLC | $42.54 | 2025 | Yupelri |
| Novo Nordisk INC | $29.33 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $23.14 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $19.55 | 2025 | Quviviq |
| Mylan Specialty L.P. | $19.44 | 2024 | Yupelri |
| Lundbeck LLC | $19.28 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $18.48 | 2024 | Arexvy |
| Pfizer INC. | $17.02 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $16.22 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $15.62 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.59 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $14.33 | 2024 | |
| Merck Sharp & Dohme LLC | $14.24 | 2025 | M-M-R II, Vaxneuvance |
| Sunovion Pharmaceuticals INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.